Latest News

The approval is supported by 12-month data from the prospective VAPOR 2 trial.

At a median follow-up of 18.8 months, the confirmed ORR was 31%.

"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.

A recap of the FDA submissions and regulatory decisions in urology from November 2025.

The test is intended to aid in the decision for prostate biopsy in men aged 50 years or older who present with elevated PSA levels.

In this episode, Farnoosh Nik-Ahd, MD, joins host Adam Weiner, MD, to discuss emerging guidance on prostate cancer screening in transgender women.

"Based on the code description, we recommend basing the code selection on the documentation and the effort required to complete the service, and not the number of foreign bodies removed from the bladder," write Jonathan Rubenstein, MD, and Mark Painter.

"Site neutrality is a pivotal issue for all independent practices, and really, it's a pivotal issue for all Americans because it affects both the global cost of care as well as the acceleration and the cost of care," says Mara R. Holton, MD.

According to the authors, the optimal duration of treatment could be tied to individual patient factors such as cancer risk.

AVZO-103 is a Nectin-4/TROP2 biospecific antibody-drug conjugate for adult patients with urothelial carcinoma whose tumors have progressed on enfortumab vedotin.

John Lam, MD, outlines the legislative efforts underway, the impact of prior authorization on patient care, and the role organized medicine can play in pushing for meaningful change.

The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.

Notably, 81% of patients said that they were interested in trying new or different treatment options.